Immunomodulation in the treatment and/or prevention of bronchial asthma

Robert G. Townley, Russell J. Hopp, Devendra K. Agrawal, Thomas B. Casale, Michael T. Hopfenspirger

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The immunologic hallmark of atopic allergy and asthma is an increased production of IgE and T helper (h) type 2 cell cytokines (interleukin (IL)-4, IL-5, IL-9 and IL-13) by Th cells reacting to common environmental allergens. All of us inhale allergens and healthy non-atopics produce allergen-specific IgG1, IgG4 and the Th1 cytokine interferon-α, as well as IL-12 from macrophages. We now have many modalities of immunomodulation to decrease the effect of IL-4 or IL-5 or production and level of IgE or agents to shift the immune response from a Th2 to a Th1 response, thereby decreasing the allergic inflammatory response in the airways. In the present review we focus on conventional immunotherapy, mycobacterial vaccines, DNA vaccines using cytosine guanosine, inhibitors of IL-4 and IL-5 and anti-IgE: Omalizumab.

Original languageEnglish (US)
Pages (from-to)63-73
Number of pages11
JournalAllergology International
Issue number2
StatePublished - 2002
Externally publishedYes


  • Bacillus Calmette-Guérin vaccine
  • Bronchial asthma
  • Cytosine guanosine oligonucleotide
  • Eosinophils
  • IgE/anti-IgE
  • Immunotherapy
  • Th1/Th2 cytokines

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'Immunomodulation in the treatment and/or prevention of bronchial asthma'. Together they form a unique fingerprint.

Cite this